SCHEDULE DETAILS Event Schedules

 

  • Breast cancer

  • 9:00-09:45

    Advanced HER2-positive/HER2-low breast cancer

    Patient with brain metastasis and stable extracranial disease:  when to change antiHER2-based therapy
    Patient with active brain metastasis: locoregional therapy vs systemic therapy
    Patient with active brain metastasis:  T-DXd  vs.
    tucatinib-based therapy
    Can we use TDM1 after T-DXd 
    Role of repeated biopsies to guide ADCs in HER2-low BC

    Moderator:  Shereef Elsamany

    Panel: 

  • 09:45 –10:30

    Role of anthracyclines in early breast cancer

    • When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer

      When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer

    Moderator:Dr. Meteeb Alfohaidi

    Panel:

  • 10:30-11:00

    Satellite Symposium

  • 8:30-9:00

    Setting-up clinical trials in Middle east: Challenges and opportunities

    Moderators:

    Dr. Emad Tashkandi Dr. Hosam Alghanmi

    Panel:

  • 09:00-09:45

    Pancreatic cancer

    • Neoadjuvant therapy in resectable/borderline resectable pancreatic cancer
    • Best neoadjuvant strategy
    • 1st line and subsequent therapies in pancreatic cancer: Doublet vs Triplets
    • biomarkers for metastatic patients

    Moderator: Dr. Abdullah Alsharm

    Panel:

  • 09:45-10:30

    Biliary tract cancer

    • Immunetherapy in advanced BTC: Yes/No
    • Which agent?
    • Patient selection/tumour location?
    • Role of maintenance therapy?
    • Role of liquid biopsy/biomarker assessment

    Moderator: Dr. Mohammed Algarni

    panel:

  • 10:30-10:45

    Break

More Details